EGFR Resisters shared a post on X about a recent paper by Otto Manninen et al. published in Oncology:
“NSCLC treated with EGFR inhibitors: the effect of concurrent medications on patient outcomes
‘Conclusions: Among EGFR-TKI-treated NSCLC, the use of TCN, TCS, and DARD can affect treatment outcomes that should be considered in optimal patient care.’ ”
Authors: Otto Manninen, Sanna Iivanainen, Martti Arffman, Jussi Pekka Koivunen.
More posts featuring EGFR Resisters.